Ceeto Capital Group LLC Purchases 890 Shares of Humana Inc. (NYSE:HUM)

Ceeto Capital Group LLC grew its position in shares of Humana Inc. (NYSE:HUM - Free Report) by 37.7% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,250 shares of the insurance provider's stock after buying an additional 890 shares during the quarter. Ceeto Capital Group LLC's holdings in Humana were worth $827,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently modified their holdings of HUM. FPC Investment Advisory Inc. bought a new position in Humana in the 4th quarter worth about $27,000. Centricity Wealth Management LLC purchased a new position in Humana during the fourth quarter worth about $30,000. LFA Lugano Financial Advisors SA raised its holdings in shares of Humana by 56.3% in the 4th quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider's stock valued at $32,000 after acquiring an additional 45 shares in the last quarter. OFI Invest Asset Management purchased a new stake in Humana in the fourth quarter valued at approximately $33,000. Finally, Atwood & Palmer Inc. raised its position in shares of Humana by 64.5% during the 4th quarter. Atwood & Palmer Inc. now owns 153 shares of the insurance provider's stock valued at $39,000 after buying an additional 60 shares in the last quarter. 92.38% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several analysts have issued reports on HUM shares. JPMorgan Chase & Co. cut their target price on Humana from $257.00 to $256.00 and set a "neutral" rating for the company in a research note on Tuesday, February 18th. Cantor Fitzgerald reiterated a "neutral" rating and issued a $290.00 price objective on shares of Humana in a report on Wednesday, February 12th. Guggenheim began coverage on Humana in a research note on Wednesday, April 9th. They issued a "buy" rating and a $326.00 target price for the company. Royal Bank of Canada restated an "outperform" rating and set a $283.00 price target on shares of Humana in a research report on Wednesday, February 12th. Finally, Piper Sandler boosted their price objective on Humana from $270.00 to $288.00 and gave the company a "neutral" rating in a research report on Wednesday, January 15th. Seventeen analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average price target of $284.90.

Humana Stock Down 7.4 %

Shares of NYSE:HUM traded down $21.01 during trading on Thursday, reaching $264.60. 2,515,864 shares of the stock traded hands, compared to its average volume of 1,753,080. The stock has a market cap of $31.94 billion, a P/E ratio of 26.59, a price-to-earnings-growth ratio of 2.05 and a beta of 0.62. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.76 and a current ratio of 1.76. The stock has a 50-day moving average of $265.80 and a two-hundred day moving average of $270.33. Humana Inc. has a 52-week low of $213.31 and a 52-week high of $406.46.

Humana (NYSE:HUM - Get Free Report) last announced its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. As a group, sell-side analysts expect that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Investors of record on Friday, June 27th will be given a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a yield of 1.34%. Humana's dividend payout ratio (DPR) is 35.58%.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.